[go: up one dir, main page]

AR014903A1 - Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria - Google Patents

Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria

Info

Publication number
AR014903A1
AR014903A1 ARP980103777A ARP980103777A AR014903A1 AR 014903 A1 AR014903 A1 AR 014903A1 AR P980103777 A ARP980103777 A AR P980103777A AR P980103777 A ARP980103777 A AR P980103777A AR 014903 A1 AR014903 A1 AR 014903A1
Authority
AR
Argentina
Prior art keywords
substituted
heterocyclic
compounds
group
aryl
Prior art date
Application number
ARP980103777A
Other languages
English (en)
Original Assignee
Athena Neurosciences Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc, American Home Prod filed Critical Athena Neurosciences Inc
Publication of AR014903A1 publication Critical patent/AR014903A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Abstract

Se describen compuestos que adhieren VLA-4. Algunos de estos compuestos inhiben también la adhesion de leucocitos y en particular la adhesion de leucocitosintermediada por VLA-4. Dichos compuestos son utiles para el tratamiento de enfermedades inflamatorias en un paciente mamífero, por ejemplo en el ser humano,tales como asma, enfermedad de Alzheimer, arterosclerosis, demencia por SIDA, diabetes, enfermedad inflamatoria del intestino, artritis reumatoidea,transplantes de tejidos, metástasis de tumores e isquemia de miocardio. Los compuestos pueden ser administrados también para el tratamiento de enfermedadescerebrales inflamatorias tales como esclerosis multiples. Los compuestos son de formula I donde: R1 está seleccionado del grupo que consiste en alquilo,alquilo substituido, arilo, arilo substituido, cicloalquilo, cicloalquilo substituido, heterocíclico, heterocíclico substituido, heteroarilo y heteroarilosubstituido; R2 está seleccionado del grupo que consiste en hidrogeno, alquilo,alquilo substituido, cicloalquilo, cicloalquilo substituido, cicloalquenilo,cicloalquenilo substituido, heterocíclico, heterocíclico substituido, arilo, arilo substituido, heteroarilo, heteroarilo substituido, y R1 y R2 conjuntamentecon el átomo denitrogeno unido a R2 y el grupo SO2 unido a R1 pueden formar un grupo heterocíclico o heterocíclico substituido; R3 está seleccionado del grupoque consiste en alquilo, alquilo substituido, cicloalquilo, cicloalquilo substituido, arilo, arilo substituido, heteroarilo, heteroarilo substituido,heterocíclico, heterocíclico substituido, y cuando R2 no forma un grupo heterocíclico con R1 y R2 y R3 conjuntamente con el átomo de nitrogeno adherido a R2 yel átomo de carbono adherido a R3, pueden formar un grupo heterocíclico o heterocíclico substituido; R5 es -(CH2)x-AR-R5 donde R5 esta seleccionado del grupoque consiste en -NR12C(Z)NR8R8 y -NR12C(Z)R13 donde R12 está seleccionado del grupo que consiste en hidrogeno, alquilo y arilo, R8 y R8 estánindependientemente seleccionados del grupo que consiste en hidrogeno, alquilo, alquilo substituido, arilo, arilo substituido, cicloalquilo, cicloalquilo
ARP980103777A 1997-07-31 1998-07-30 Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria AR014903A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92035397A 1997-07-31 1997-07-31

Publications (1)

Publication Number Publication Date
AR014903A1 true AR014903A1 (es) 2001-04-11

Family

ID=25443597

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103777A AR014903A1 (es) 1997-07-31 1998-07-30 Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria

Country Status (17)

Country Link
EP (1) EP1001974B1 (es)
JP (1) JP2003517424A (es)
KR (1) KR20010022414A (es)
CN (1) CN1265674A (es)
AR (1) AR014903A1 (es)
AT (1) ATE327245T1 (es)
AU (1) AU8584698A (es)
BR (1) BR9812118A (es)
CA (1) CA2290750A1 (es)
DE (1) DE69834642T2 (es)
HU (1) HUP0004531A3 (es)
IL (1) IL133638A0 (es)
NO (1) NO20000411L (es)
NZ (1) NZ502580A (es)
PL (1) PL338413A1 (es)
WO (1) WO1999006434A1 (es)
ZA (1) ZA986837B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
DE69818049T2 (de) 1997-06-23 2004-07-15 Tanabe Seiyaku Co., Ltd. Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
HUP0103752A3 (en) 1998-04-16 2002-11-28 Texas Biotechnology Corp Houst N,n-disubstituted amides and pharmaceutical compositions containing them that inhibit the binding of integrins to their receptors
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
KR100649819B1 (ko) * 1999-02-18 2007-02-28 에프. 호프만-라 로슈 아게 티오아미드 유도체
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
PT1265606E (pt) * 1999-08-13 2007-01-31 Biogen Idec Inc Inibidores da adesão celular
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
JP2003531141A (ja) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド エナミン誘導体
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
MXPA05007843A (es) * 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
EP1591440A4 (en) * 2003-01-28 2006-03-29 Shanghai Inst Materia Medica ALANINE COMPOUNDS, MANUFACTURING METHOD AND USE
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
KR100646882B1 (ko) * 2004-08-09 2006-11-23 엘지전자 주식회사 전기오븐레인지의 오븐부 배기구조
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
WO2006023852A2 (en) 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2008521825A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
CN101374519A (zh) 2005-12-22 2009-02-25 弗特克斯药品有限公司 毒蕈碱性受体调节剂
ES2398319T3 (es) 2005-12-28 2013-03-15 Vertex Pharmaceuticals Incorporated Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2642649A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101426499A (zh) 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
CN101500565A (zh) 2006-06-29 2009-08-05 弗特克斯药品有限公司 毒蕈碱性受体的调节剂
CN101553231A (zh) 2006-08-15 2009-10-07 弗特克斯药品有限公司 毒蕈碱受体调节剂
EP2051715A2 (en) 2006-08-18 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2700724A1 (en) 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
DE102009058290A1 (de) 2009-12-04 2011-06-09 Vladimir Volchkov Viertaktmotor, Verfahren zu seinem Betrieb und Kraftstoffeinspritzverfahren
DE102009058289A1 (de) 2009-12-04 2011-06-09 Vladimir Volchkov Viertaktmotor und Verfahren zu seinem Betrieb
DE102010008225A1 (de) 2010-02-09 2011-08-11 Volchkov, Vladimir, 71638 Viertakt-Gegenkolbenmotor und Verfahren zu seinem Betrieb
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
HRP20250191T1 (hr) 2018-10-30 2025-04-11 Gilead Sciences, Inc. Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria

Also Published As

Publication number Publication date
JP2003517424A (ja) 2003-05-27
HUP0004531A3 (en) 2001-12-28
EP1001974A1 (en) 2000-05-24
IL133638A0 (en) 2001-04-30
DE69834642D1 (de) 2006-06-29
DE69834642T2 (de) 2007-05-03
BR9812118A (pt) 2000-07-18
WO1999006434A1 (en) 1999-02-11
NZ502580A (en) 2001-06-29
NO20000411D0 (no) 2000-01-27
EP1001974B1 (en) 2006-05-24
HUP0004531A2 (hu) 2001-04-28
NO20000411L (no) 2000-03-28
ATE327245T1 (de) 2006-06-15
ZA986837B (en) 2000-05-02
CN1265674A (zh) 2000-09-06
CA2290750A1 (en) 1999-02-11
PL338413A1 (en) 2000-11-06
AU8584698A (en) 1999-02-22
KR20010022414A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
AR014903A1 (es) Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria
AR016133A1 (es) Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
AR016387A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos
AR013384A1 (es) Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4
DE69001187D1 (de) 6-epifumagillole, ihre herstellung und ihre verwendung.
ES2131207T3 (es) Derivados de amidas del acido valproico y 2-valproenoico y su uso como anticonvulsivos.
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
EP0613883A4 (en) HYDROXAMIC ACID DERIVATIVE.
AR057873A2 (es) Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos
MY129970A (en) Hypolipidaemic compounds
EP1807412A1 (en) Cyclic diarly ureas suitable as tyrosine kinase inhibitors
KR20010030944A (ko) α-케토아미드 다촉매활성의 프로테아제 억제제
UA79157C2 (en) Method for the synthesis of thiophenecarboxylic acid esters and the use thereof
SI1077218T1 (sl) Peptido-mimetiäśne spojine, ki vsebujejo sekvenco rgd, uporabne kot inhibitorji integrinov
EP0322184B1 (en) N-(2-alkyl-3-mercapto-1,5-di-oxoalkyl)glycinamide derivatives and their use as collagenase inhibitors
Guivisdalsky et al. Synthesis and antineoplastic properties of ether-linked thioglycolipids
Prugh et al. Methyl 3-0-benzyl-2, 4, 6-trideoxy-6-iodo-α-d-erythro-hexopyranoside, a chiral synthon for the synthesis of inhibitors of HMG-CoA reductase
DK183789A (da) 2-alkyl-3-benzoylbenzofuraner og laegemidler indeholdende disse
AR022405A1 (es) Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos
HUT57716A (en) Process for producing sulfonylamino-substituted bicyclic hydroxame acid derivatives and pharmaceutical compositions comprising such compounds
EP1813616A3 (en) Pyrazoloquinolines with immunomodulating activity
ATE39921T1 (de) Verfahren zur herstellung von azetidinonen mit chiralitaetszentrum.
AR029611A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4
US2507337A (en) 1, 5-dialkyl tetrazoles and preparation thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure